<DOC>
	<DOCNO>NCT02173821</DOCNO>
	<brief_summary>This follow-up study patient , treat one daily dose Zomacton one daily dose Genotropin previously complete FE 999905 CS07 trial , presence anti-hGH antibody post-dosing visit 12-month treatment period . No investigational medicinal product administer connection follow-up study . Eligible patient attend one visit follow-up study .</brief_summary>
	<brief_title>A Follow-up Study Examine Presence Anti-human Growth Hormone Antibodies Following Study ( FE 999905 CS07 ) Zomacton Children With Growth Hormone Deficiency</brief_title>
	<detailed_description />
	<mesh_term>Endocrine System Diseases</mesh_term>
	<mesh_term>Dwarfism , Pituitary</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Previous participation trial FE 999905 CS07 presence antihGH antibody postdosing visit throughout 12month treatment period Signed informed consent obtain assent accord local rule practice Information medical history , concomitant medication , growth hormone therapy since completion trial FE 999905 CS07 There predefined exclusion criterion study</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>